CD19 and diffuse large B-cell lymphoma: Three separate clinical trials have evaluated CD19 CAR-T compared to standard of care (SOC) with platinum-based chemotherapy followed by auto-SCT for patients with primary refractory or early relapsing DLBCL defined as relapse less than 12 months from completion of frontline chemoimmunotherapy.